Cardiac rehabilitation after transcatheter aortic valve implantation before, during and after the COVID-19 pandemic: a whole-population study.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 41932822.
- Also identified by DOI 10.1136/heartjnl-2025-327186.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Evidence on cardiac rehabilitation (CR) after transcatheter aortic valve implantation (TAVI) is limited. We examined CR participation across England before, during and after the COVID-19 pandemic, and its association with clinical outcomes. This retrospective cohort study used whole-population electronic health records to evaluate characteristics and outcomes of all TAVI recipients in England (2018-2023), stratified by CR participation. The primary outcome was unplanned all-cause rehospitalisation. Secondary outcomes included all-cause mortality, heart failure (HF) rehospitalisation and non-cardiovascular rehospitalisation. Follow-up was up to 5 years, with a minimum of 12 months. Multivariable models adjusted for demographics, clinical factors and procedural complications. Among 24 925 TAVI recipients (56% male, mean age 81 years and 95% white ethnicity), only 1090 (4.4%) attended CR. CR rates dropped during the first COVID-19 lockdown (1.57 per 10 000 person-days) and recovered post pandemic (3.24). HF rehospitalisation rates per 10 000 person-days were similar between CR and non-CR groups (1.05 vs 1.02), while all-cause (4.49 vs 4.72), non-cardiovascular rehospitalisation (4.53 vs 4.82) and mortality rates (3.61 vs 3.84) were slightly lower among CR participants. After adjustment, CR was associated with lower risk of all-cause (HR 0.88, 95% CI 0.79 to 0.98; p=0.019) and non-cardiovascular rehospitalisation (HR 0.84, 95% CI 0.76 to 0.94; p=0.002); however, there was no evidence of an association between CR and HF rehospitalisation (HR 0.94, 95% CI 0.75 to 1.19; p=0.607) or mortality (HR 0.95, 95% CI 0.84 to 1.07; p=0.383). CR after TAVI declined during the first COVID-19 lockdown but rebounded quickly. CR was associated with lower all-cause and non-cardiovascular rehospitalisation but was not associated with lower HF rehospitalisation or mortality. More research is needed to confirm these clinical findings.